U.S. Stock Market Midday Update

Obsidian Therapeutics rose 13.66%. There has been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

Stocks with High Trading Volume in the Industry

AbbVie rose 2.50%. Based on recent key news:

1. On August 18, Haisco announced a cooperation agreement with AbbVie, granting AbbVie exclusive rights to develop, produce, and commercialize HSK51155 globally, with a potential total deal value exceeding $700 million. This partnership has enhanced market confidence in AbbVie's future growth, driving the stock price up.

2. On August 18, AbbVie announced a third-quarter dividend plan, with a dividend of 0.38 Brazilian Reais per unit, boosting investor confidence in the company's financial health and further supporting the stock price increase.

3. On August 17, market analysis showed that although AbbVie was rated as "moderate buy," top analysts believe there are other better investment options, which may limit further stock price increases. The pharmaceutical industry's collaborations and dividend plans have driven the stock price up.

Amgen rose 1.64%, with increased trading volume. Based on recent key news:

1. On August 17, AstraZeneca announced the launch of Tezspire in China. This drug was co-developed by AstraZeneca and Amgen, and the launch news boosted Amgen's stock price.

2. On August 17, Barclays raised Amgen's target price to $380, maintaining a neutral rating. The target price increase reflects market confidence in Amgen's future performance, driving the stock price up.

3. On August 17, analysts maintained a hold rating on Amgen. Although the rating remained unchanged, the market's optimistic expectations for its future performance still had a positive impact on the stock price. The pharmaceutical industry is restructuring, and competition is fierce, requiring attention to risks.

Gilead Sciences rose 3.03%. Based on recent key news:

1. On August 18, BMO Capital analyst Evan Seigerman reiterated a buy rating on Gilead Sciences, with a target price of $174. This move has enhanced market confidence, driving the stock price up.

2. On August 18, FactSet's latest survey showed that the median EPS estimate for Gilead Sciences in 2026 was revised from -$0.46 to -$0.45 by 25 analysts, indicating improved market expectations and boosting the stock price.

3. On August 6, J.P. Morgan analyst Chris Schott released a report giving Gilead Sciences a buy rating, further supporting the stock price increase. Market expectations have improved, and analyst ratings are positive.

Stocks with High Market Capitalization in the Industry

Vertex Pharmaceuticals rose 2.75%. Based on recent key news:

1. On August 18, BMO Capital analyst Evan Seigerman maintained a buy rating on Vertex Pharmaceuticals, setting a target price of $600 The company's stock price closed at $515.55 yesterday. The analyst consensus is a strong buy, with an average target price of $565.32, indicating a potential upside of 9.65% from the current level. This news boosted market confidence and drove up the stock price of Fortera Pharmaceuticals.

2. On August 18, the animal health industry faced macro tightening pressures, causing Zoetis's stock price to drop to a 52-week low. Despite the launch of the new product Simparica Trio, cautious consumer spending led to a downward revision of the full-year outlook. This industry dynamic may affect Fortera Pharmaceuticals' market performance.

3. On August 16, MarketBeat noted that Vertex Pharmaceuticals was not included in the list of the top five stocks recommended by leading analysts, despite its rating being a moderate buy. This information may impact investor sentiment. Macro tightening affects the animal health industry